Illumina logo
Illumina ILMN
$ 134.29 -1.58%

Quarterly report 2025-Q3
added 10-31-2025

report update icon

Illumina Financial Ratios 2011-2025 | ILMN

Annual Financial Ratios Illumina

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-13.4 -28.7 41.6 85.3 - 46.1 50.8 50.8 48.5 - 78.0 144.3 73.9 70.1

P/S

3.7 7.4 7.0 17.3 - 13.0 12.6 9.8 10.1 - 14.8 12.7 6.1 9.7

EPS

-7.7 -7.3 5.1 4.5 - 6.8 5.6 5.0 3.2 - 2.6 1 1.2 1.0

EV (Enterprise Value)

15.3 B 32.3 B 30.5 B 54.1 B - 46.9 B 44 B 24.4 B 23.5 B - 28.8 B 18.9 B 7.09 B 9.14 B

EBITDA per Share

-3.01 -4.03 0.85 5.22 - 8.35 7.22 4.96 5.11 - 4.63 1.85 2.17 2.05

EV/EBITDA

70.5 - 36.9 39.2 32.7 30.6 - 44.5 79.0 25.8 34.7

PEG

- - 2.16 3.82 -46.03 1.41 - 0.47 -6.92 -2.6 1.08

P/B

2.6 3.3 2.1 7.4 - 10.0 11.2 10.7 12.1 - 18.8 11.8 6.0 7.3

P/CF

19.6 69.8 58.1 51.8 - 54.9 49.6 46.3 34.8 - 76.7 61.1 23.0 40.5

ROE %

-51.54 -20.21 7.09 13.98 - 21.72 21.98 21.06 24.97 - 24.16 8.17 8.05 10.43

ROA %

-19.40 -11.48 5.01 8.65 - 13.70 11.87 10.81 12.52 - 10.58 4.15 3.94 6.79

ROCE %

-35.10 -18.61 -1.15 12.36 - 15.62 17.13 16.42 19.92 - 19.66 4.97 10.13 16.23

Current Ratio

- - - - - 6.7 2.5 3.3 3.4 - 2.6 5.0 6.8 2.4

DSO

61.3 56.0 45.8 27.4 - 59.0 56.3 58.0 63.4 - 56.8 61.4 60.1 67.0

DIO

137.0 105.6 106.8 65.5 - 121.8 136.4 149.7 147.4 - 123.8 110.4 135.7 172.3

DPO

56.3 59.8 69.7 33.8 - 50.5 65.0 68.8 75.8 - 53.5 52.8 52.5 80.8

Operating Cycle

198.3 161.6 152.6 93.0 - 180.8 192.7 207.7 210.8 - 180.5 171.8 195.9 239.3

Cash Conversion Cycle

142.0 101.7 82.9 59.1 - 130.3 127.7 138.9 135.0 - 127.0 119.0 143.4 158.5

All numbers in USD currency

Quarterly Financial Ratios Illumina

2025-Q3 2025-Q2 2024-Q3 2024-Q2 2024-Q1 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.98 1.49 4.43 -12.48 -0.79 -1.48 0.02 - - -3.4 0.55 - 2.09 1.27 1.01 - 1.22 0.32 1.18 1.63 1.59 2.01 1.58 1.43 1.35 1.42 1.42 0.47 1.12 0.87 2.5 0.72 0.88 0.83 0.61 - 0.81 0.71 0.95 1.08 0.66 0.36 0.47 0.64 0.25 0.29 -0.18 0.58 0.24 0.19 0.21 0.31 0.17 0.25 0.19

EBITDA per Share

1.92 1.8 5.1 -9.64 -0.33 -0.25 -0.04 - - -3.04 1.49 - -3.16 1.84 1.6 - 1.42 1.16 1.54 - 2.86 1.91 1.64 - 2.32 1.99 1.69 - 1.79 1.34 0.53 - 1.54 1.39 0.97 - 1.33 1.29 1.34 - 1.16 1 0.83 - 0.66 0.67 -0.27 - 0.69 0.54 0.5 - 0.63 0.75 0.65

ROE %

-88.56 -97.05 -111.03 -144.16 -7.83 -62.32 -63.88 -63.13 -55.55 4.13 12.83 15.03 13.36 14.18 14.41 11.43 16.61 18.07 21.09 23.13 23.54 23.56 22.29 21.98 18.87 19.50 18.59 26.41 29.59 29.42 30.60 21.77 22.22 22.56 22.42 20.22 30.70 31.93 29.42 25.10 19.88 14.59 13.75 8.17 8.37 8.58 8.01 11.47 9.23 8.92 9.76 10.04 1.95 2.62 2.27

ROA %

-59.09 -62.78 -35.93 -35.91 -4.35 -6.56 -8.04 -7.50 0.49 2.59 8.19 9.30 8.33 8.65 8.98 7.35 10.62 11.40 12.98 13.70 13.45 13.11 12.07 11.87 10.15 10.39 9.82 13.81 15.35 15.30 15.88 11.27 11.60 11.71 11.46 9.83 14.42 14.06 12.69 10.58 8.66 6.90 6.69 4.15 4.28 4.40 4.13 5.89 5.18 4.96 5.41 5.52 0.94 1.36 1.14

ROCE %

-60.12 -71.59 -82.40 -118.23 -4.23 -7.84 -12.04 -9.40 -9.00 -14.14 -4.99 2.39 5.83 14.42 12.86 9.51 16.45 19.94 22.63 16.79 23.20 22.68 23.99 18.25 24.84 25.01 24.17 13.68 20.86 21.47 24.15 21.14 28.41 28.50 29.09 26.59 35.97 38.07 36.46 22.53 25.49 19.08 16.14 3.93 7.64 8.37 7.72 10.72 14.27 14.12 16.51 15.72 3.55 5.65 6.52

DSO

60.2 - - 52.4 58.4 54.5 56.1 - - 49.3 41.1 - 47.1 42.8 21.6 - 48.8 61.8 55.5 54.9 57.6 62.4 58.6 54.1 55.0 56.5 54.0 48.2 52.5 56.6 60.8 59.2 56.7 58.9 32.1 - 64.8 60.8 54.2 51.5 55.0 59.0 57.3 56.3 61.1 63.0 62.6 63.4 68.6 69.9 63.7 58.4 70.2 59.6 -

DIO

151.4 - - 133.6 134.0 123.6 121.9 - - 113.5 93.6 - 105.4 104.8 50.5 - 144.7 182.3 141.2 - 126.5 123.6 129.7 - 137.6 138.1 134.4 - 131.0 133.3 119.8 - 157.2 155.3 75.1 - 128.2 120.0 110.6 - 118.9 118.6 110.5 - 95.8 114.6 127.8 - 160.9 165.3 149.6 - 164.1 142.2 -

DPO

54.3 - - 46.7 49.6 49.9 56.5 - - 66.2 54.0 - 60.5 53.2 24.7 - 49.5 59.0 53.0 - 52.5 51.3 58.0 - 65.6 65.8 64.3 - 62.9 64.0 59.4 - 97.0 105.1 40.3 - 64.8 60.0 52.8 - 51.4 51.3 50.0 - 45.8 54.8 57.0 - 66.6 68.5 65.9 - 64.3 60.4 -

Operating Cycle

211.6 200.2 - 186.0 192.3 178.2 178.0 - - 162.9 134.7 - 152.5 147.6 72.1 - 193.5 244.1 196.8 54.9 184.1 186.0 188.4 54.1 192.6 194.6 188.4 48.2 183.5 189.9 180.5 59.2 213.9 214.3 107.2 - 193.1 180.8 164.8 51.5 173.9 177.6 167.8 56.3 156.9 177.6 190.4 63.4 229.5 235.2 213.3 58.4 234.3 201.8 -

Cash Conversion Cycle

157.3 150.2 - 139.3 142.7 128.2 121.5 - - 96.7 80.7 - 92.1 94.4 47.4 - 144.0 185.1 143.7 54.9 131.6 134.7 130.4 54.1 127.0 128.8 124.1 48.2 120.6 125.9 121.2 59.2 116.9 109.2 66.8 - 128.2 120.8 111.9 51.5 122.5 126.4 117.8 56.3 111.1 122.8 133.4 63.4 162.9 166.8 147.4 58.4 170.0 141.4 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Illumina, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.36 -4.05 % $ 176 M chinaChina
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 17.05 -2.15 % $ 99.4 M israelIsrael
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.63 -2.11 % $ 2.07 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 221.54 -1.96 % $ 40.2 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 38.85 2.32 % $ 1.08 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Danaher Corporation Danaher Corporation
DHR
$ 227.08 -2.28 % $ 166 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 11.92 -6.58 % $ 338 M israelIsrael
DexCom DexCom
DXCM
$ 66.91 -2.94 % $ 25.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 20.44 3.23 % $ 1.1 B usaUSA
Celcuity Celcuity
CELC
$ 105.26 4.46 % $ 4.15 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.59 -25.21 % $ 115 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 101.58 0.21 % $ 18.8 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 0.34 -2.96 % $ 9.98 M usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 27.13 0.26 % $ 820 M usaUSA
Guardant Health Guardant Health
GH
$ 102.09 0.7 % $ 12.5 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.6 -1.52 % $ 20 B niderlandNiderland
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 192.57 -0.96 % $ 9.89 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 28.79 -2.93 % $ 1.21 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 182.21 0.35 % $ 20.2 B usaUSA
Biodesix Biodesix
BDSX
$ 7.94 -1.0 % $ 1.03 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 263.51 -0.46 % $ 22.1 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 186.28 -1.92 % $ 15.4 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 701.07 -0.91 % $ 57.8 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 66.11 4.76 % $ 4.57 B usaUSA
Agilent Technologies Agilent Technologies
A
$ 139.44 -2.4 % $ 42.4 B usaUSA
Biomerica Biomerica
BMRA
$ 2.55 -1.07 % $ 5.86 M usaUSA
Bioventus Bioventus
BVS
$ 7.59 2.29 % $ 475 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 395.23 -1.85 % $ 29.6 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 7.26 -0.62 % $ 658 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.47 -7.6 % $ 2.94 M usaUSA